CA2768821A1 - Pyrrolo[2,3-d]pyrimidine derivative - Google Patents

Pyrrolo[2,3-d]pyrimidine derivative Download PDF

Info

Publication number
CA2768821A1
CA2768821A1 CA2768821A CA2768821A CA2768821A1 CA 2768821 A1 CA2768821 A1 CA 2768821A1 CA 2768821 A CA2768821 A CA 2768821A CA 2768821 A CA2768821 A CA 2768821A CA 2768821 A1 CA2768821 A1 CA 2768821A1
Authority
CA
Canada
Prior art keywords
group
compound
cancer
hydrogen atom
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2768821A
Other languages
English (en)
French (fr)
Inventor
Kazunari Tsuboike
Gen Mizuno
Hiroshi Nishida
Shigeyuki Kono
Akiko Toyota
Fumie Tanzawa
Kosaku Fujiwara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ube Corp
Original Assignee
Ube Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries Ltd filed Critical Ube Industries Ltd
Publication of CA2768821A1 publication Critical patent/CA2768821A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2768821A 2009-07-28 2010-07-27 Pyrrolo[2,3-d]pyrimidine derivative Abandoned CA2768821A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009175619 2009-07-28
JP2009-175619 2009-07-28
PCT/JP2010/062602 WO2011013656A1 (ja) 2009-07-28 2010-07-27 ピロロ［２，３－ｄ］ピリミジン誘導体

Publications (1)

Publication Number Publication Date
CA2768821A1 true CA2768821A1 (en) 2011-02-03

Family

ID=43529310

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2768821A Abandoned CA2768821A1 (en) 2009-07-28 2010-07-27 Pyrrolo[2,3-d]pyrimidine derivative

Country Status (10)

Country Link
US (1) US20120149902A1 (enExample)
EP (1) EP2511276A4 (enExample)
JP (1) JPWO2011013656A1 (enExample)
KR (1) KR20120065321A (enExample)
CN (1) CN102482281A (enExample)
AU (1) AU2010279188A1 (enExample)
CA (1) CA2768821A1 (enExample)
IN (1) IN2012DN01251A (enExample)
TW (1) TW201107328A (enExample)
WO (1) WO2011013656A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2900671A1 (en) * 2012-09-26 2015-08-05 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
JP2015531361A (ja) 2012-09-26 2015-11-02 バイエル・ファルマ・アクティエンゲゼルシャフト 過剰増殖性疾患の治療に有用な置換インダゾール−ピロロピリミジン
SG11201809223PA (en) * 2016-04-19 2018-11-29 Univ California Erbb inhibitors and uses thereof
MX2019002281A (es) * 2016-08-26 2019-06-20 Mitsubishi Tanabe Pharma Corp Compuesto heterociclico nitrogenado biciclico.
CN113277990A (zh) * 2021-06-22 2021-08-20 仪征市海帆化工有限公司 一种1,4-双(对甲苯磺酰基)三氮环壬烷的合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL188959B1 (pl) * 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
PT938486E (pt) * 1996-08-23 2008-03-27 Novartis Ag Pirrolopirimidinas substituídas e processos para a sua preparação
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
MY145634A (en) * 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
WO2006104971A1 (en) * 2005-03-28 2006-10-05 Bristol-Myers Squibb Company Atp competitive kinase inhibitors

Also Published As

Publication number Publication date
JPWO2011013656A1 (ja) 2013-01-07
US20120149902A1 (en) 2012-06-14
EP2511276A1 (en) 2012-10-17
WO2011013656A1 (ja) 2011-02-03
AU2010279188A1 (en) 2012-02-23
TW201107328A (en) 2011-03-01
EP2511276A4 (en) 2012-12-19
KR20120065321A (ko) 2012-06-20
IN2012DN01251A (enExample) 2015-05-15
CN102482281A (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
AU2020256431B2 (en) Bicyclic heterocycles as fgfr4 inhibitors
US11136326B2 (en) Pyrrolopyrimidine derivatives as TAM inhibitors
JP6449244B2 (ja) Ｆｇｆｒ抑制剤としての二環式複素環
TWI876724B (zh) 作為tam抑制劑之吡咯并三嗪化合物
KR101961500B1 (ko) 세린/트레오닌 키나제 억제제
AU2014309788B2 (en) Novel quinoline-substituted compound
CA2778291C (en) Akt inhibitors
US20220017520A1 (en) Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine
US9840503B2 (en) Heterocyclic compounds and uses thereof
TW200835485A (en) Novel aminopyrimidine derivatives as PLK1 inhibitors
TW202329937A (zh) 雙環胺ｃｋ１２抑制劑
US20120149902A1 (en) Pyrrolo[2,3-d]pyrimidine derivative
CA2753304C (en) Tricyclic pyrazolopyrimidine derivatives as hsp inhibitors
CA3163959A1 (en) Cyano-pyrimidine inhibitors of egfr/her2
CN110078743A (zh) 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
KR20250130345A (ko) 돌연변이체 선택적 egfr 저해제
EA048995B1 (ru) Новые производные диоксолоизохинолинона и их применение
NZ713074B2 (en) Bicyclic heterocycles as fgfr inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150728